Evidence map›Paper›PMID 32652782›Full record

GuidelineThe oncologist2020

GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain.

Miguel Martin, Angel Guerrero-Zotano, Ángel Montero, Carlos Jara, Elena Filipovich, Federico Rojo, Fernando Moreno, Jose Ángel García-Sáenz, Jose Enrique Alés, José Ignacio Chacón and 7 more

Open access · bronzeAbstract readGuideline
In one paragraph

Guideline in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Miguel MartinMedical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Medicina, Universidad Complutense, Madrid, Spain.
Angel Guerrero-ZotanoMedical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
Ángel MonteroRadiation Oncology, Hospital HM Sanchinarro, Madrid, Spain.
Carlos JaraMedical Oncology, Universidad Rey Juan Carlos, Hospital Fundación Alcorcón, Madrid, Spain.
Elena FilipovichMedical Oncology, Complejo Asistencial de Ávila, Ávila, Spain.
Federico RojoCentro de Investigación Biomedica en Red de Oncologia, CIBERONC-ISCIII, Spain.
Fernando MorenoMedical Oncology, Hospital Universitario Clínico San Carlos de Madrid, Madrid, Spain.
Jose Ángel García-SáenzCentro de Investigación Biomedica en Red de Oncologia, CIBERONC-ISCIII, Spain.
Jose Enrique AlésMedical Oncology, Complejo Asistencial de Ávila, Ávila, Spain.
José Ignacio ChacónMedical Oncology, Hospital Virgen de la Salud de Toledo, Toledo, Spain.
Josefina CruzMedical Oncology, Hospital Universitario de Canarias, Tenerife, Spain.
Julia GimenezSurgery, Instituto Valenciano de Oncología, Valencia, Spain.
Luis Cruz-MerinoMedical Oncology, Hospital Virgen de Macarena de Sevilla, Seville, Spain.
Manel AlgaraRadiation Oncology, Hospital del Mar de Barcelona, Barcelona, Spain.
Marta SantistebanMedical Oncology, Clínica Universidad de Navarra, Navarra, Spain.
Sara López TarruellaMedical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Departamento de Medicina, Universidad Complutense, Madrid, Spain.
GEICAM Spanish Breast Cancer Group Steering Committee
Catholic University of Ávila · ESFundación Instituto Valenciano de Oncología · ESInstituto de Salud Carlos III · ESCentro de Investigación Biomédica en Red de Cáncer · ESClinica Universidad de Navarra · ESHospital Clínico San Carlos · ESHospital Del Mar · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario de Canarias · ESHospital Universitario Fundación Alcorcón · ESHospital Universitario HM Sanchinarro · ESHospital Universitario Virgen Macarena · ESHospital Virgen de la Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the most common cancer in women in Spain. During the COVID-19 pandemic caused by the SARS-CoV-2 virus, patients with BC still require timely treatment and follow-up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. IMPLICATIONS FOR PRACTICE: This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID-19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare.

Indexed as

Breast NeoplasmsClinical Decision-MakingCOVID-19Delivery of Health CareFemaleHumansMedical OncologyPatient AdmissionSARS-CoV-2SpainBreast cancerCOVID-19Expert recommendationsPandemicSARS-CoV-2

Identifiers

PMID32652782
PMCPMC7405405
OpenAlexW3041116152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.